Cytophage Technologies Ltd. — Investor Relations & Filings

Cytophage Technologies Ltd. is a pioneering biotechnology company focused on developing synthetic bacteriophage products to prevent and treat bacterial infections, aiming to reduce and ultimately replace the use of conventional antibiotics. The company utilizes molecular genetic techniques and proprietary synthetic biology technology to create tailor-made, highly effective phages that are harmless to humans and animals. Cytophage's solutions address three primary markets: Animal Health (e.g., livestock illness prevention and growth enhancement), Food Safety (preventing disease spread without antibiotics), and Human Health (treating bacterial illnesses and hospital decontamination). A key competitive advantage is the rapid production timeline for targeted phages, enabling quick response to bacterial threats. The company is also engaged in advanced research, including the development of genetically engineered phage-based vaccines.